Core Viewpoint - Runfeng Co., Ltd. (301035.SZ) has announced changes to its fundraising projects and the allocation of remaining surplus funds to enhance the efficiency and return on investment of raised funds [1] Group 1: Fundraising Project Changes - The company has decided to terminate certain fundraising investment projects due to business development and market demand for products [1] - The original investment projects included: annual production of 9,000 tons of Chlorothalonil, annual production of 38,800 tons of herbicides (Phase I) - 30,000 tons/year of glyphosate soluble granules, and annual production of 25,000 tons of glyphosate continuous technological transformation project [1] - The new project is the global registration of pesticide products, with a total investment of 746.454 million yuan [1] Group 2: Financial Details - The amount of funds redirected from the original projects to the new project is 470.2447 million yuan [1] - The implementation entities for the new project are Runfeng Co., Ltd. and Qingdao Runong Chemical Co., Ltd. [1] - The changes are subject to approval by the shareholders' meeting before implementation [1]

Core Viewpoint - Runfeng Co., Ltd. (301035.SZ) has announced changes to its fundraising projects, terminating some existing projects to enhance the efficiency and return on investment of raised funds, redirecting the remaining funds to a global registration project for pesticide products [1] Group 1: Fundraising Project Changes - The company has approved the termination of certain fundraising investment projects due to business development and market demand [1] - The original investment projects included: annual production of 9,000 tons of Chlorothalonil, annual production of 38,800 tons of herbicides (Phase I) - 30,000 tons/year of glyphosate soluble granules, and annual production of 25,000 tons of glyphosate continuous technological transformation project [1] - The new project, named the global registration project for pesticide products, has a total investment of 746.454 million yuan, with a change in fundraising direction amounting to 470.2447 million yuan [1]

Group 1 - The company held a performance briefing on September 19, 2025, to discuss its mid-year results with investors [1] - The event was attended by the company's chairman, general manager, and financial director, allowing for in-depth communication with investors [1] Group 2 - Despite challenges in the agricultural chemical industry, the company achieved revenue and profit growth in the first half of the year due to improved market conditions and strong demand for specific products [2] - The company is focusing on enhancing cooperation with core customers and increasing production capacity, particularly for its Klobucan and Sterilization products, which are expected to drive further performance growth [2] - The company addressed concerns regarding its declining stock price and shareholder sell-offs, attributing these fluctuations to macroeconomic factors and stating that recent sell-offs were normal financial behaviors by long-term investors [2]

Group 1: Company Performance - The company achieved revenue and profit growth in the first half of the year despite challenges in the agricultural chemical industry, such as overcapacity and price pressure [2] - The company's production and sales of key products, such as Keguan Dan and Mie Jun Dan, have increased significantly, with the production capacity being fully utilized [2] - The company is actively advancing the expansion plan for Mie Jun Dan to meet the growing customer demand, which is expected to enhance its market share and competitiveness globally [2] Group 2: Market and Investor Relations - The recent decline in stock price and shareholder sell-offs are attributed to macroeconomic factors, industry cycles, and market sentiment, which are beyond the company's control [3] - The company emphasizes its commitment to maintaining market value and has disclosed a stock price stabilization plan in its prospectus, which will be executed if certain conditions are met [3] - The company reassures investors of its stable operational activities and strategic planning, expressing confidence in long-term growth and performance [3]

Core Insights - Guangkang Biochemical reported a revenue of 399 million yuan for the first half of 2025, marking a year-on-year increase of 25.55% [1] - The net profit attributable to shareholders reached 29.01 million yuan, up 32.13% year-on-year, with a significant increase of 190% in net profit after deducting non-recurring gains [1] - The company achieved a positive net cash flow from operating activities of 38.67 million yuan, reversing from a negative position in the same period last year [1] Revenue Breakdown - The revenue from the raw material business was 329 million yuan, an increase of 18.26%, accounting for 82.42% of total revenue [1] - The formulation business generated 69.05 million yuan, showing a substantial growth of 82.64% [1] - The growth in revenue is attributed to increased sales of fungicide products and expansion in the formulation business, alongside cost reduction through optimized production processes [1] R&D and Innovation - The company invested 16.70 million yuan in R&D, reflecting an 11.83% increase year-on-year [2] - Guangkang Biochemical achieved certification for the GB/T29490-2023 intellectual property compliance management system and was recognized as a provincial-level technology center [2] - The company has developed expertise in key technology areas such as chlorination and diazotization, supporting continuous product upgrades [2] Market Strategy and Product Development - The company adheres to a "differentiated and niche" competition strategy, which has proven effective [2] - Core products such as Kexingdan and Mieqingdan received a 15-year renewal approval from the EU, with usage restrictions lifted, expected to boost overseas market demand [2] - The production lines for Mieqingdan at the Yingde base are operating at full capacity, while the Kexingdan production capacity at the Shaoguan base is continuously increasing [2] Product Portfolio and International Collaboration - Guangkang Biochemical is a major supplier of succinate dehydrogenase inhibitors and trichloromethyl sulfur fungicides, with a strong product matrix including Benfluralin, Thifensulfuron, and Kexingdan [2] - The company is the sole domestic producer of Toxaphene, and its clean production processes for Kexingdan and Mieqingdan have received national invention patents [2] - The company maintains stable collaborations with multinational agrochemical firms such as UPL and ADAMA, with products distributed in major markets like the US and EU [2]

Core Viewpoint - Runfeng Co., Ltd. has postponed several fundraising projects initially planned for investment, citing complex and changing market conditions in the agricultural chemical industry as the primary reason for these delays [2][4][5]. Group 1: Project Delays - Runfeng Co., Ltd. announced the postponement of multiple fundraising projects, including the "9000 tons of Clomazone project," "38800 tons of herbicide project," "plant protection product R&D center project," and "25000 tons of glyphosate continuous technology transformation project" [1][3]. - Since mid-2022, Runfeng Co. has repeatedly adjusted the timelines for several fundraising projects, with some projects undergoing three adjustments over four years [1][2]. - The "25000 tons of glyphosate continuous technology transformation project" has been postponed from May 2024 to May 2026, while the "herbicide project" has also seen its timeline extended from July 2025 to July 2026 [3][5]. Group 2: Market Conditions - The agricultural chemical industry, where Runfeng operates, is currently at a cyclical low, characterized by oversupply, which has led to the postponement of investment projects [2][6]. - The company noted that the prices of most crop protection raw materials are at historical lows, and the market is expected to remain oversupplied due to increased production capacity in China and India [6]. - Runfeng Co. anticipates that the market will transition from "de-stocking" to "de-capacity" by 2025, leading to intensified competition and potential exits of non-competitive firms from the market [6]. Group 3: Strategic Adjustments - Runfeng Co. has indicated that the changes in fundraising project allocations are a response to evolving market demands and product pricing, reflecting a strategic adjustment to its business planning [2][5]. - Despite the delays, the company maintains that the postponed projects still align with its long-term strategic planning and remain necessary and feasible for future investment [5][6].

证券代码：300804 证券简称：广康生化 公告编号：2025-002 广东广康生化科技股份有限公司 关于近期经营情况的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东广康生化科技股份有限公司（以下简称"公司"）为便于广大投资者全 面了解公司经营情况，增强投资信心，现结合投资者关注的问题，将公司近期经 营情况公告如下： 一、美国加征关税对公司的影响 近日，美国政府发布关于所谓"对等关税"的行政令，宣布美国对贸易伙伴 加征10%的"最低基准关税"，并对某些贸易伙伴征收更高关税，引发市场高度 关注。 公司在全球市场布局中对单一国家或地区的依赖度较低，对美国客户的直接 销售额占总收入的比例较低。公司在产品选择上一直实行"差异化、小众化"的 竞争策略，主要产品可替代性弱，且由于国际市场对中国原药的依赖性强，本次 美国关税调整对公司生产经营不会产生重大不利影响。 公司将密切关注相关政策变化，与客户保持紧密沟通，通过协商定价机制等 举措，共同分担潜在成本压力。同时，公司将扩大内销以及开拓新兴市场，提升 公司在全球化布局中的抗风险能力。 二、克菌丹与 ...

Core Viewpoint - Guangkang Biochemical (300804) has reported a total order volume of 3,630 tons for its Kegun Dan and Mie Jun Dan products, amounting to approximately 92.9067 million yuan, indicating strong market demand and potential for future growth [1] Group 1 - The company is actively promoting the expansion and transformation of Kegun Dan and Mie Jun Dan production, which is expected to enhance its market influence [1] - The anticipated production expansion is likely to have a positive impact on the company's future performance [1]

Core Viewpoint - The adjustment of U.S. tariffs will not have a significant adverse impact on the company's production and operations due to the low proportion of direct sales to U.S. customers and the strong dependency of the international market on Chinese raw materials [1] Group 1 - The company's direct sales to U.S. customers account for a low proportion of total revenue, indicating limited exposure to tariff changes [1] - The main products have weak substitutability, which strengthens the company's position in the market [1] - The international market's strong reliance on Chinese raw materials mitigates potential negative impacts from tariff adjustments [1] Group 2 - The company plans to implement pricing negotiation mechanisms to share potential cost pressures with customers [1] - There are plans to expand domestic sales and explore emerging markets to enhance risk resilience [1] Group 3 - The core products, Kexingdan and Mieqingdan, have received renewed approval from the EU, which is expected to aid in capacity release and performance growth [1]

股票简称：广康生化 股票代码：300804 广东广康生化科技股份有限公司 （Yingde Greatchem Chemicals Co., Ltd.） （英德市农用化工产业链专用基地（英德市沙口镇红丰管理区）） 首次公开发行股票并在创业板上市 之 上市公告书 保荐人（主承销商） （深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 2023 年 6 月 广东广康生化科技股份有限公司 上市公告书 特别提示 广东广康生化科技股份有限公司（以下简称"广康生化"、"本公司"、"发行 人"或"公司"）股票将于 2023 年 6 月 27 日在深圳证券交易所创业板市场上市。 创业板公司具有业绩不稳定、经营风险高、退市风险大等特点，投资者面临 较大的市场风险。投资者应充分了解创业板市场的投资风险及本公司所披露的风 险因素，审慎做出投资决定。 本公司提醒投资者应当充分关注定价市场化蕴含的风险因素，知晓股票上 市后存在跌破发行价的可能，切实提高风险意识，强化价值投资理念，避免盲 目炒作，监管机构、发行人和保荐人（主承销商）均无法保证股票上市后不会 跌破发行价格。 如无特别说明，本上市公告书中的简称或名词 ...